Aducanumab (Mouse IGG2a) is a monoclonal antibody that selectively targets aggregated amyloid-beta protein (Aβ). Its variable region matches that of Aducanumab, while the constant region is derived from the Mouse IGG2a sequence. Aducanumab (Mouse IGG2a) demonstrates strong selectivity for Aβ fibrils, with EC50 values of >1 μM for Aβ1-40 monomer and 0.2 nM for Aβ1-42 fibrils. This compound can be utilized in Alzheimer's disease (AD) research.

Aducanumab (Mouse IGG2a) exhibits very weak monovalent binding affinity, with its Fab fragment binding to surface-captured monomeric Aβ 1-40-biotin having a K_D of approximately 9 μM. At a concentration of 5 μM, Aducanumab shows low affinity for Aβ peptides, with K_D values of 1.8 μM and 5.9 μM for Aβ 1-16 and Aβ 1-28, respectively. The compound also displays weak affinity for monomer and tetramer multi-antigen peptides (MAPs), with EC_50 values for dimeric and tetrameric Aβ 1-15 MAP greater than 1 μM and approximately 7 nM, respectively. Aducanumab effectively binds immobilized Aβ amidst excess free monomers, with an IC_50 of greater than 1 μM.